Sep 2025 (Q3 FY25) — Oct 30, 2025
Ambev Q3 FY25 — Resilient net revenue/hl (+7%) and cost discipline offset soft Brazil beer volumes
Read the full callAmbev (ABEV) earnings
- Sep 2025 (Q3 FY25)
- Dec 2025
Ambev earnings: last reported Thu, 30 Oct 2025, for the quarter ended Sep 2025.
Price
$3.25 −1.22% · −$0.04
Performance +44.4% 1Y
1Y: $2.25 on 17 Oct 2025 → $3.25. High $3.43 (6 May 2026), low $2.18 (29 Oct 2025).
- Previous close
- $3.29
- 52-week range
- $2.18 – $3.43
- One year
- +43.17%
Overview
- Symbol
- ABEV
- Sector
- Consumer Staples
- Industry
- Beverages
- Exchange
- US
- Currency
- USD
Call summaries
Jun 2025 (Q2 FY25) — Jul 31, 2025
Ambev Q2 FY25 — Strong Brand Equity and Digital Growth Drive Margin Expansion Amidst Weather Headwinds
Read the full callEvery analysed call
Ambev earnings calls (ABEV)
Financials
What the filings say
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities | 9,858 | 9,749 | 9,635 | 9,797 | 10,334 | 10,820 | 10,175 | 10,280 |
| Fixed assets | 5,575 | 5,617 | 4,769 | 5,245 | 5,685 | 5,488 | 4,878 | 5,047 |
| Total assets | 24,661 | 25,312 | 24,104 | 24,878 | 26,096 | 27,337 | 26,276 | 26,487 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 4,727 | 4,573 | 3,630 | 4,111 | 3,905 | 5,093 | 4,220 | 4,464 |
| Cash from investing | -947 | -1,204 | -1,309 | -1,388 | -947 | -1,188 | -883 | -904 |
| Cash from financing | -3,519 | -3,056 | -1,656 | -2,879 | -3,090 | -3,321 | -1,674 | -4,887 |
| Net cash flow | 261 | 313 | 665 | -157 | -132 | 583 | 1,663 | -1,327 |
| Capital expenditure | -920 | -1,261 | -903 | -1,378 | -1,236 | -1,237 | -768 | -838 |
| Free cash flow | 3,807 | 3,312 | 2,727 | 2,733 | 2,669 | 3,855 | 3,452 | 3,626 |
Insider filings
12 filings between Mar 24, 2026 and Sep 3, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$2.59M
5 sales by 5 insiders
Compensation
not trading decisions- 7
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Moreira Ricardo Manuel Frangatos Pires | — | $1.44M | Jul 30, 2026 |
| Zagman Paulo Andre | — | $464.6K | May 5, 2026 |
| Cavalcanti de Lacerda Eduardo Braga | — | $434.3K | Mar 27, 2026 |
| Crippa Prado Carla Smith de Vasconcellos | — | $187.7K | Sep 3, 2026 |
| Malik Parente Guilherme | — | $57.9K | Mar 24, 2026 |
Latest filings (12)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 3, 2026 | Crippa Prado Carla Smith de Vasconcellos See Remarks | Sale | 60,757 | $187.7K |
| Jul 30, 2026 | Moreira Ricardo Manuel Frangatos Pires Director | Sale | 468,040 | $1.44M |
| May 5, 2026 | Zagman Paulo Andre See Remarks | Sale | 136,250 | $464.6K |
| Mar 30, 2026 | Zagman Paulo Andre See Remarks | Award | 34,714 | $108.0K |
| Mar 30, 2026 | Parolari Guilherme Fleury de Figueiredo Ferraz See Remarks | Award | 44,714 | $139.1K |
| Mar 30, 2026 | Crippa Prado Carla Smith de Vasconcellos See Remarks | Award | 11,261 | $35.0K |
| Mar 30, 2026 | Cavalcanti de Lacerda Eduardo Braga See Remarks | Award | 30,431 | $94.6K |
| Mar 30, 2026 | Malik Parente Guilherme See Remarks | Award | 8,455 | $26.3K |
| Mar 30, 2026 | Klutzenschell Lisboa Carlos Eduardo Chief Executive Officer | Award | 205,372 | $638.7K |
| Mar 30, 2026 | Duarte Valdecir See Remarks | Award | 38,074 | $118.4K |
| Mar 27, 2026 | Cavalcanti de Lacerda Eduardo Braga See Remarks | Sale | 152,386 | $434.3K |
| Mar 24, 2026 | Malik Parente Guilherme See Remarks | Sale | 20,971 | $57.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for AMBEV S.A.
Free account. Everything above stays public.
Write why you follow AMBEV S.A. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading